摘要
溶瘤微生物疗法凭借其独特的肿瘤靶向性和免疫调控能力,已成为肿瘤免疫治疗领域的新兴策略。溶瘤微生物(包括溶瘤细菌和溶瘤病毒)能够选择性感染并裂解肿瘤细胞,同时激活宿主免疫反应,从而增强治疗效果。为克服天然溶瘤微生物临床应用中面临的宿主免疫清除、体内稳定性不足及脱靶效应等诸多挑战,药物制剂技术在溶瘤微生物疗法优化方面发挥了关键作用。综述系统阐述溶瘤细菌与溶瘤病毒的作用机制、临床前研究与临床进展,重点探讨溶瘤微生物应用挑战及药物制剂优化策略,旨在为溶瘤微生物制剂的开发与临床转化提供参考。
Oncolytic microorganism-mediated therapy has emerged as a promising strategy in tumor immunotherapy due to its unique targeting capabilities and immunomodulatory effects.Oncolytic microorganisms,including oncolytic bacteria and viruses,selectively infect and lyse tumor cells,activating host immune responses and significantly enhancing their therapeutic efficacy.To overcome the numerous challenges faced in the clinical application of natural oncolytic microorganisms—including host immune clearance,insufficient in vivo stability,and off-target effects—pharmaceutical formulation technologies play a pivotal role in optimizing oncolytic microbial therapies.This review discusses the mechanisms,preclinical and clinical progress of oncolytic bacteria and viruses,with a focus on the application challenges and optimized pharmaceutical strategies,aiming to provide some reference for the development and clinical translation of oncolytic microbial formulations.
作者
凌昊
章浩天
何仲贵
孙孟驰
孙进
LING Hao;ZHANG Haotian;HE Zhonggui;SUN Mengchi;SUN Jin(Wuya College of Innovation,Shenyang Pharmaceutical University,Shenyang 110016,China;School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,China;Ministry of Education International Collaborative Laboratory for Design and Evaluation of Smart Drug Delivery Systems,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处
《药学进展》
2026年第2期125-140,共16页
Progress in Pharmaceutical Sciences
基金
国家自然科学基金资助项目(No.82073777,No.82372111,No.82404557)
辽宁省青年科学基金B类(No.2025-YQ-16)
沈阳药科大学优秀青年提升计划(No.YQ202301)。
关键词
溶瘤微生物
溶瘤细菌
溶瘤病毒
药物制剂技术
免疫调控
oncolytic microorganism
oncolytic bacteria
oncolytic virus
pharmaceutical formulation technology
immunomodulatory effect
